150 related articles for article (PubMed ID: 35729008)
1. Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients.
Gendarme S; Pastré J; Billaud EM; Gibault L; Guillemain R; Oudard S; Medioni J; Lillo-Lelouet A; Israël-Biet D
Therapie; 2023; 78(3):267-278. PubMed ID: 35729008
[TBL] [Abstract][Full Text] [Related]
2. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
[TBL] [Abstract][Full Text] [Related]
3. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
Bachmann F; Glander P; Budde K; Bachmann C
J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus and everolimus in kidney transplantation.
Moes DJ; Guchelaar HJ; de Fijter JW
Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
[TBL] [Abstract][Full Text] [Related]
5. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
6. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
Caletti C; Granata S; Tomei P; Lupo A; Zaza G
G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
[TBL] [Abstract][Full Text] [Related]
7. Severe everolimus-associated pneumonitis in a renal transplant recipient.
Alexandru S; Ortiz A; Baldovi S; Milicua JM; Ruíz-Escribano E; Egido J; Plaza JJ
Nephrol Dial Transplant; 2008 Oct; 23(10):3353-5. PubMed ID: 18658177
[TBL] [Abstract][Full Text] [Related]
8. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
Dabydeen DA; Jagannathan JP; Ramaiya N; Krajewski K; Schutz FA; Cho DC; Pedrosa I; Choueiri TK
Eur J Cancer; 2012 Jul; 48(10):1519-24. PubMed ID: 22483544
[TBL] [Abstract][Full Text] [Related]
9. Proteinuria associated with mTOR inhibitors after kidney transplant.
Guney M; Sahin G; Yilmaz B; Canbakan M; Gucun M; Kayatas K; Eren P; Titiz I
Exp Clin Transplant; 2014 Dec; 12(6):539-42. PubMed ID: 25489805
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
[TBL] [Abstract][Full Text] [Related]
12. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
13. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.
Krueger DA; Capal JK; Curatolo P; Devinsky O; Ess K; Tzadok M; Koenig MK; Narayanan V; Ramos F; Jozwiak S; de Vries P; Jansen AC; Wong M; Mowat D; Lawson J; Bruns S; Franz DN;
Eur J Paediatr Neurol; 2018 Nov; 22(6):1066-1073. PubMed ID: 30005812
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
Borders EB; Bivona C; Medina PJ
Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
16. Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients.
Atzori L; Conti B; Zucca M; Pau M
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1626-30. PubMed ID: 25174440
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibitors in pediatric liver transplant recipients.
Dumortier J; Couchonnal E; Lacaille F; Rivet C; Debray D; Boillot O; Lachaux A; Ackermann O; Gonzales E; Wildhaber BE; Jacquemin E; McLin V
Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
[TBL] [Abstract][Full Text] [Related]
18. Everolimus and sirolimus in transplantation-related but different.
Klawitter J; Nashan B; Christians U
Expert Opin Drug Saf; 2015 Jul; 14(7):1055-70. PubMed ID: 25912929
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
[TBL] [Abstract][Full Text] [Related]
20. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
